Kiyoshi Okamoto

TL;DR: Data demonstrate that lenvatinib provides antitumor activity mainly via angiogenesis inhibition but also inhibits FGFR and RET signaling pathway in preclinical human thyroid cancer models.

TL;DR: It is demonstrated that lenvatinib can exert antitumor activity againstRET gene fusion-driven tumor models by inhibiting oncogenic RET gene fusion signaling.

TL;DR: It is shown that eribulin induces remodeling of tumor vasculature through a novel antivascular activity in MX‐1 and MDA‐MB‐231 human breast cancer xenograft models, suggesting that Eribulin‐induced remodelling of abnormal tumor vasculation leads to a more functional microenvironment that may reduce the aggressiveness of tumors due to elimination of inner tumor hypoxia.

TL;DR: Seven novel 12-membered macrolides from Streptomyces platensis Mer-11107 are discovered, with pladienolide B the most potently inhibiting hypoxia induced-VEGF expression and proliferation of the U251 cancer cell line, and appear to have major potential for use in cancer treatment.

TL;DR: Kinetic analysis and X-ray analysis suggest that lenvatinib is very distinct in its binding mode of interaction compared to the several approved VEGFR2 kinase inhibitors.